BioCryst Pharmaceuticals, Inc. (BCRX) Stock: Price, Forecast & Analyst Target
BioCryst Pharmaceuticals, Inc. (BCRX) — MoonshotScore 16/100 (Weak band), calculated Nov 18, 2026. Price $7.30 (-2.67%), as of the Nov 18, 2026 trading session; market cap $1.88B.
Educational signal · not a buy or sell recommendation · How to read this
BioCryst Pharmaceuticals, Inc. · BCRX · NASDAQ
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel, oral, small-molecule medicines for rare and serious diseases. Its key marketed product is ORLADEYO for hereditary angioedema, complemented by a pipeline addressing complement-mediated diseases, fibrodysplasia ossificans progressiva, and various RNA viruses.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · BioCryst Pharmaceuticals (BCRX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Middling on every pillar — nothing weak enough to single out, nothing strong enough to stand on. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Okay; Valuation: Fair; Growth Durability: Growing; Momentum: Rising.
- EPS beat 2 of the last 4 reports
- Altman Z -3.15 · Piotroski F 5
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 16 | Weak | |
| 16 | Weak | |
| 16 | Weak | |
| 16 | Weak | |
| 16 | Weak | |
| 16 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $7.30 | |
| Change on the day | -2.67% | |
| 52-week range | $6.23 – $11.22 | |
| Market capitalisation | $1.88B | — |
| Price / earnings (trailing) | 11.46 | |
| Shares traded on the day | 2.95M |
Price & events
Other perspectives
Council score for BioCryst Pharmaceuticals (BCRX): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Four of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Simons-style lens, Englander-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is BioCryst Pharmaceuticals (BCRX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. BioCryst Pharmaceuticals, Inc. (BCRX) is listed on NASDAQ. It employs 435 people and is led by Charles K. Gayer. The market values it at $1.88B.
What do the latest results show for BioCryst Pharmaceuticals (BCRX)?
Short answer · as of
Against analyst estimates the company has EPS beat 2 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $159M | $13M | $0.06 (diluted) |
| Q4 FY2025 | $407M | $246M | $1.12 (diluted) |
| Q1 FY2026 | $156M | -$722M | -$2.98 (diluted) |
| Q2 FY2026 | $218M | $78M | $0.30 (diluted) |
What are the financial strengths and risks for BioCryst Pharmaceuticals (BCRX)?
Short answer
The distress and quality screens read Altman Z -3.15 · Piotroski F 5. Trailing ratios: ROA 56.5% · current ratio 2.71.
What should you watch next at BioCryst Pharmaceuticals (BCRX)?
Short answer · as of
Current published price targets run low $11.00 · high $29.00 · consensus $19.00 · median $17.00 against a quoted price of $7.30 (as of Nov 18, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does BioCryst Pharmaceuticals compare with its peers?
Short answer
BioCryst Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $61.99 Nov 18, 2026 | $1.79B | 98 5-pillar Nov 18, 2026 | |
| $15.13 Nov 18, 2026 | $2.03B | 97 5-pillar Nov 18, 2026 | |
| $14.10 Nov 18, 2026 | $1.54B | 97 5-pillar Nov 18, 2026 | |
| $13.56 Nov 18, 2026 | $3.01B | 97 5-pillar Nov 18, 2026 | |
| $33.11 Nov 18, 2026 | $1.94B | 96 5-pillar Nov 18, 2026 | |
| $18.40 Nov 18, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $58.65 Nov 18, 2026 | $2.99B | 95 5-pillar Nov 18, 2026 | |
| $25.57 Nov 18, 2026 | $2.06B | 89 5-pillar Nov 18, 2026 | |
| $47.06 Nov 18, 2026 | $1.40B | 76 5-pillar Nov 18, 2026 | |
| $40.06 Nov 18, 2026 | $1.30B | 69 5-pillar Nov 18, 2026 | |
| $17.83 Nov 18, 2026 | $3.08B | 68 5-pillar Nov 18, 2026 | |
| $17.83 Nov 18, 2026 | $1.10B | 66 5-pillar Nov 18, 2026 | |
| BioCryst Pharmaceuticals (BCRX) — this page | $7.30 | $1.88B | 16 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $11.00 – $29.00
- Consensus target
- $19.00
- Median target
- $17.00
Consensus record · Captured .
Measured against a quoted price of $7.30 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 31, 2026
- Transactions
- 28
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 0
- Other transactions
- 28
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BCRX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BCRX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about BioCryst Pharmaceuticals (BCRX)?
- BioCryst Announces New Real-World Evidence for ORLADEYO® at ACAAI 2026
- BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
- The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal
What Investors Ask About BioCryst Pharmaceuticals (BCRX)
These answers are editorial: 1 of these 9 answers is drawn from the BCRX research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for BCRX?
BCRX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is BCRX a good stock to buy?
Stock Expert AI does not rate BCRX buy, sell or hold. BioCryst Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BCRX stock price today?
The last price recorded for BioCryst Pharmaceuticals, Inc. (BCRX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BCRX price target?
The analyst consensus price target for BioCryst Pharmaceuticals, Inc. (BCRX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What does BioCryst Pharmaceuticals, Inc. do?
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of novel, oral, small-molecule medicines. Its core business involves bringing innovative therapies to market for rare and serious diseases, as well as acute conditions.
What are the key factors to evaluate for BCRX?
BioCryst Pharmaceuticals, Inc. (BCRX) holds a MoonshotScore in the low range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Dividend Policy: The company does not currently offer a dividend yield, aligning with the typical strategy of growth-oriented biotechnology companies that reinvest earnings into R&D and pipeline expansion. Not financial advice.
How frequently does BCRX data refresh on this page?
BCRX's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BCRX's recent stock price performance?
BioCryst Pharmaceuticals, Inc. (BCRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Commercialized products, including ORLADEYO for hereditary angioedema, providing current revenue streams. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BCRX overvalued or undervalued right now?
The trailing P/E of BioCryst Pharmaceuticals, Inc. (BCRX) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 11 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
ETFs that hold BCRX
Funds in our ETF coverage that list BCRX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| LITL ETF | 0.85% |